Renalytix Share Discussion Threads

[vaston] 15/9/2022 08:24

I’m so Glad I paid £3 a share earlier in the year , after being tipped this will be big.

[wan] 15/9/2022 05:23

An impressive and comprehensive new website that is aligned with the new laser focus on the commercial roll out of KidneyIntelX, and one assumes it supports that focus and ramp in activity to drive revenue and scale in the forthcoming September, December, and March quarters by testing "tens of thousands of patients this year, moving into next year" :source and quote from the interview with CEO at H.C. Wainwright 24th Annual Global Investment Conference September 12, 2022

New website -

[latifs100] 14/9/2022 17:08

i thought £250 was cheap!

[donald pond] 01/9/2022 13:57

Enterprise value here now £14m according to sharepad

[yasx] 31/8/2022 10:04

This is not generating sufficient revenue and the market has no interest in Co's burning cash with no sign of a sustainable, growing revenue stream. Cutting back costs is one thing, but eventually there is a need for tapping the market for more. They need FDA approval and soon.

Point to note: That chap 74Tom has a remarkable ability to invest in everything that just seems to go down (such as this Co.) - I came across his contributions on several threads, each dedicated to a Co that was loss making with pie in the sky hopes of huge revenues to come - most crashed spectacularly as one might have expected. He serves as a good contrarian indicator if you ever come across his ebullient contributions on any share.

[mr roper] 26/8/2022 15:19

Interesting thoughts, wan. Its going to be an interesting 6 mths here. Partnerships of a kind are critical to drive revenue growth.

If they cant deliver a partnership does this, as well as their other objectives of full medicare coverage and fda then i suspect there will be an inflectionpoint in Q1 where they need to make a tough choice on how they raise forward funding.

Options as I see are equity raise and dilution, strategic investor/partner investment or sale of business. For the latter i would have thought DaVita or Azn would be very keen to bolt on but it's all just guesswork for now

[wan] 24/8/2022 09:32

I should have added that the average cost for each test is around $50.

[wan] 24/8/2022 08:32

I note Millennium reduced their short position further on 22nd Aug to its lowest level since opening it in January 22(and materially increasing it though to April).

Other information shows no open short positions, but this might also be because they do not track positions below 0.5%.

Cleary, and conversely, they see risks to the upside from here (and indeed they realised a healthy profit).

Time will tell, but hopefully it's another indication that we have reached the bottom given Millenniums sophistication, and investment reach etc, and some reprieve/share price improvement may not be too far away.

[cisk] 23/8/2022 16:33

other way round I think Roper, UK followed US lead yesterday and will adjust to follow it again today

[roper] 23/8/2022 15:27

Down 9% in U.S
Not woken up to the move here

[mr roper] 21/8/2022 15:23

Just reading the business update again.
Focus now on upper Midwest, 14m insurance covered lives. Sales team in place with medical liason staff. Targeting 7 VHA centres in this region.
Would be good to hear what the project test run rate is.

Going by their LinkedIn page a few of the sales guys are heading out due to refocusing on specific regions.

Next 6mths are key. Would think they need to be hitting 2000 tests a month in at least one of those months in q1 next year.

[mr roper] 17/8/2022 15:23

Sounded positive. Suspect Randy Baron and a few of the institutions have been involved to get this clarity of focus brought to the fore.

[red171] 17/8/2022 15:23

The dog has admitted seeing the rabbit but may not catch it in time.


If they had $59m 31 Mar take away 2 quarters of net outflow of say $25m plus cost of $12m annualised savings ($6m?) plus net revenue over period $1m & we will have $29m at 30 Sep which only supports another 2 quarters without transformation or either:

-revenue targeted in IL & testing at Mt Sinai & WakeF

-parthership

or more finance by huge dilution

[wan] 17/8/2022 12:41

An interesting development, with both cash flow and cash burn coming into focus.

One also assumes that being able to provide inaugural financial guidance could also be on the agenda.

[tomboyb] 17/8/2022 12:18

Renalytix PLC Business update
17/08/2022 12:00pm
UK Regulatory (RNS & others)

Renalytix (LSE:RENX)
Intraday Stock Chart

Wednesday 17 August 2022

Click Here for more Renalytix Charts.
TIDMRENX

RNS Number : 3072W

Renalytix PLC

17 August 2022

This contains inside information

Renalytix plc

("Renalytix" or the "Company")

Business update

NEW YORK, NY and SALT LAKE CITY, UT August 17, 2022 (GLOBE NEWSWIRE) - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) provides the following business update.

Based on recently secured private payer and Medicaid insurance coverage contracts for KidneyIntelX, Renalytix plc is disclosing that the upper Midwest region of the United States, and specifically Illinois and Iowa, are now primary commercial expansion markets. Private insurance coverage contracts secured and effective during the quarter ending September 30, 2022 include Blue Cross Blue Shield Illinois (estimated over 8 million covered lives) and Molina Healthcare Illinois (estimated 0.5 million covered lives). This complements coverage already secured with Wellmark Blue Cross Blue Shield in Iowa and South Dakota (estimated 2.1 million covered lives). Additionally, Renalytix has contracted with Illinois Medicaid as a provider for their program. Illinois Medicaid is estimated to provide medical insurance to over 20% of (or 3.3 million) Illinois residents and the contracts with BCBS and Molina provide insurance coverage for a significant proportion of that population. Illinois will now play a critical part in the KidneyIntelX health equity strategy to help drive down disparities in community care for individuals with diabetes and kidney disease.

With clarity on comprehensive insurance coverage now emerging on a region-by-region basis, the Company has taken steps in the current quarter ending September 30, 2022 to focus operating resources on near-term revenue opportunities, such as those disclosed above, and also reduce cash expenditure.

The Company has already executed changes designed to yield over $12 million in annual savings in fiscal 2023, with more in process. Full effects of cash burn-rate reduction are expected to be realized in the fiscal second and third quarters ending December 30, 2022 and March 31, 2023, respectively. A regional commercial focus dictated by growing insurance payer coverage also complements efforts to introduce KidneyIntelX testing through the seven Veterans Health Administration Centers serving Illinois and Iowa. Renalytix previously contracted with the US Government under a General Service Administration contract for up to 10 years. The contract allows Renalytix to provide KidneyIntelX testing to any of the 140 U.S. government departments, agencies and affiliates offering healthcare services. Under the contract KidneyIntelX pricing was set at $950 per reportable result.

[wan] 08/8/2022 07:11

Greenpa...There is a lot of evidence to not only suggest, but validate the fact that Renalytix is very likely to be in discussion with multiple strategic partners, including, but not limited to, pharma partners.

Your answer is probably contained within todays RNS -

"The study publication announced today is a key element of a comprehensive evidence development program," said Tom McLain, President of Renalytix. "This program was designed to address the evidence requirements of payers, regulators, clinicians, and guideline setting bodies. The increasing volume of real-world evidence being generated from our health systems partnerships, presented at the ADA conference, confirms clinical utility, and indicates adoption of KidneyIntelX in the clinical setting."

"We now have evidence that indicates that KidneyIntelX is not only clinically valued by PCPs but is also useful in aiding clinical decision making in the real-world setting, helping ensure that patients are on the right care path at the right time," said Michael J. Donovan, Ph.D., M.D., Chief Medical Officer of Renalytix. "The adoption rate among PCPs as reported at the 2022 ADA late-breaking poster session on our real-world evidence study and the published clinical utility study underscores both the clinical need and clinician confidence in using KidneyIntelX to provide actionable risk stratification. In the real-world setting, this was associated with a 6-fold increase in the initiation of guideline-recommended treatments, and a nearly 3-fold increase in appropriate referrals."

[greenpa] 07/8/2022 20:49

Wan
James had suggested in earnings call that PCPs are 7x more likely to prescribe meds to DKD patients with high risk classification. Any thoughts on how this study relates to that assertion? Also such a marked increase would seems to scream for pharma partners to seek to advance KidneyIntelX. Thoughts?

[wan] 05/8/2022 10:22

Edit/tweak to the above post -

We evaluated the decision-making impact of an artificial intelligence–enabled prognostic test, KidneyIntelX, in the management of DKD by primary care physicians (PCPs).

[wan] 05/8/2022 05:10

We evaluated the decision-making impact of an artificial intelligence–enabled prognostic test, KidneyIntelX, in the management of DKD by primary care physicians (PCPs) -

A Kidney Diagnostic’s Impact on Physician Decision-Making in Diabetic Kidney Disease
August 4, 2022
Manasi Datar, PhD, Saranya Ramakrishnan, MPH, Jennifer Chong, BA, Elizabeth Montgomery, BS, Thomas F. Goss, PharmD, Steven G. Coca, MD, Joseph A. Vassalotti, MD

ABSTRACT

Objectives: Estimated glomerular filtration rate (eGFR) and albuminuria, the current standard-of-care tests that predict risk of kidney function decline in early-stage diabetic kidney disease (DKD), are only modestly useful. We evaluated the decision-making impact of an artificial intelligence–enabled prognostic test, KidneyIntelX, in the management of DKD by primary care physicians (PCPs).

Study Design: This was a prospective web-based survey administered among PCPs in the United States.

Methods: We used conjoint analysis with multivariable logit models to estimate PCP preferences. The survey included hypothetical patient profiles with 6 attributes: albuminuria, eGFR, age, blood pressure (BP), glycated hemoglobin A1c (HbA1c), and KidneyIntelX result. Each PCP viewed 8 patient profiles randomly selected from 42 unique profiles having 1 level from each attribute. For each patient, PCPs were asked to indicate whether they would prescribe a sodium-glucose cotransporter-2 (SGLT2) inhibitor, increase angiotensin receptor blocker (ARB) dose, and/or refer to a nephrologist.

Results: A total of401 PCPs completed the survey (response rate, 8.8%). The relative importance of the top 2 attributes for each decision were HbA1c (52%) and KidneyIntelX result (23%) for prescribing SGLT2 inhibitors; BP (62%) and KidneyIntelX result (13%) for increasing ARB dose; and eGFR (42%) and KidneyIntelX result (27%) for nephrologist referral. A high-risk KidneyIntelX result was associated with significantly higher odds of PCPs prescribing SGLT2 inhibitors (odds ratio [OR], 1.64; 95% CI, 1.29-2.08), increasing ARB dose (OR, 1.49; 95% CI, 1.17-1.89), and referring to a nephrologist (OR, 2.47; 95% CI, 1.99-3.08) compared with no test.

Conclusions: The KidneyIntelX test had greater relative importance than albuminuria and eGFR to PCPs in making treatment decisions and was second only to eGFR for nephrologist referrals. Due to its significant impact on decision-making, KidneyIntelX has high clinical utility in DKD management.

Takeaway Points

A prognostic test, such as KidneyIntelX, that offers better risk stratification than the Kidney Disease Improving Global Outcomes classification, which is based solely on albuminuria and estimated glomerular filtration rate, would have a significant impact on physician decision-making pertaining to treatment selection and nephrologist referrals in patients with diabetic kidney disease (DKD).

By demonstrating physician demand for a novel prognostic test like KidneyIntelX, this study makes a case for increasing patient access to this diagnostic through improved coverage.

This study provides evidence of the KidneyIntelX test satisfying unmet physician needs in standard-of-care management of DKD. Policy makers can use these results to adopt novel tests such as the KidneyIntelX test into practice guidelines.

As the first of its kind to evaluate a kidney diagnostic, this study challenges the current standard-of-care norms in the staging and management of kidney disease, thereby attempting to change practice patterns in the medical community, potentially leading to improved outcomes.

CONCLUSIONS

A prognostic test such asKidneyIntelX that uses biomarkers and clinical parameters to better stratify patients by risk of kidney function decline would have a greater impact on physician decision-making than current standard-of-care tests. It addresses unmet needs identified in current practice and allows PCPs to act in the early stages of DKD progression before significant symptoms emerge. Our study shows that if tests such as KidneyIntelX were made readily accessible, PCPs would incorporate the test results into their treatment plan, ultimately making more informed decisions in the management of their patients with DKD, potentially resulting in improved outcomes.

Full study worth reading in full -

[mr roper] 04/8/2022 16:29

Yes, the bod do seem to major in talking the talk. Need to see some actual partnerships that lead to revenue ramp up.

I remember the golden days of a partnership with DaVita...18mths later we've heard nothing

[wan] 03/8/2022 08:49

Hyperkalemia in Chronic Kidney Disease: Links, Risks and Management

Authors Sarnowski A, Gama RM, Dawson A, Mason H, Banerjee D

Received 18 March 2022

Accepted for publication 22 June 2022

Published 2 August 2022 Volume 2022:15 Pages 215—228

DOI hxxps://doi.org/10.2147/IJNRD.S326464

Abstract: Hyperkalemia is a common clinical problem with potentially fatal consequences. The prevalence of hyperkalemia is increasing, partially due to wide-scale utilization of prognostically beneficial medications that inhibit the renin-angiotensin-aldosterone-system (RAASi). Chronic kidney disease (CKD) is one of the multitude of risk factors for and associations with hyperkalemia. Reductions in urinary potassium excretion that occur in CKD can lead to an inability to maintain potassium homeostasis. In CKD patients, there are a variety of strategies to tackle acute and chronic hyperkalemia, including protecting myocardium from arrhythmias, shifting potassium into cells, increasing potassium excretion from the body, addressing dietary intake and treating associated conditions, which may exacerbate problems such as metabolic acidosis. The evidence base is variable but has recently been supplemented with the discovery of novel oral potassium binders, which have shown promise and efficacy in studies. Their use is likely to become widespread and offers another tool to the clinician treating hyperkalemia. Our review article provides an overview of hyperkalemia in CKD patients, including an exploration of relevant guidelines and nuances around management.

Keywords: CKD, electrolytes, hyperkalemia, potassium, RAAS
Link to full document -

Again the above is worthy of note in my view, in terms of how can the various combinations (importantly delivered at the right time), allowing physicians to improve monitoring and ongoing treatment, be brought together? - No wonder then, that Renalytix are in discussion with multiple strategic partners.